Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041668 | 0.82 | LMNA (0.62) | LMNAALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL3955572 | 0.82 | LMNA (0.62) | LMNAALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL8537484 | 0.78 | LMNA (0.63) | LMNAALDH1A1CA1CA2CA9 | |
| SCHEMBL13940305 | 0.78 | LMNA (0.58) | LMNAALDH1A1CA1CA2CA9 | |
| SCHEMBL1414315 | 0.78 | CA2 (0.59) | LMNAALDH1A1TDP1CA1CA2 | |
| SCHEMBL2531247 | 0.78 | LMNA (0.58) | LMNAALDH1A1TDP1KMT2AKDM4E | |
| SCHEMBL469386 | 0.78 | ALDH1A1 (0.72) | LMNAALDH1A1HSD17B10KMT2AKDM4E | |
| SCHEMBL6407809 | 0.77 | LMNA (0.56) | LMNAALDH1A1TDP1KMT2AKDM4E | |
| SCHEMBL11511622 | 0.76 | ALDH1A1 (0.47) | LMNAALDH1A1HSD17B10TDP1CA1 | |
| SCHEMBL651902 | 0.75 | ALDH1A1 (0.71) | LMNAALDH1A1HSD17B10TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054397-B1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2420494-B1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8710237-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTE (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8569426-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8268935-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-0994895-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006435-A1 | DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006431-A1 | SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4379819-A | OIL SOLUBLE MONOAZO DYE | CIBA-GEIGY AG (CH) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | LMNA 1983/4885ALDH1A1 1425/4885HSD17B10 845/4885 |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | LMNA 1983/4885ALDH1A1 1425/4885HSD17B10 845/4885 |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | LMNA 3465/4885ALDH1A1 755/4885HSD17B10 3212/4885 |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | LMNA 3465/4885ALDH1A1 755/4885HSD17B10 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.